| Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management" |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Myelodysplastic Syndromes: 2021 update on Diagnosis, Risk-stratification and Management |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Allogeneic HSCT in Aplastic Anemia: Current Evidence, Controversies, and Practical Decision-Making |
|
American Journal of Hematology |
Aplastic Anemia |
| Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| HLA-haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of EBMT severe aplastic Anemia and pediatric diseases working parties |
|
American Journal of Hematology |
Aplastic Anemia |
| Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
